Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy
Status:
Terminated
Trial end date:
2019-06-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out how successful ibrutinib is at putting follicular
lymphoma into full remission. In this study, remission will be determined by achieving a
normal PET scan after treatment. A PET scan is an imaging test that looks for active
lymphoma. People who don't have a complete remission on PET after their first treatment are
at high risk for having their lymphoma return. This study will investigate if ibrutinib will
help participants achieve a complete remission without giving additional chemotherapy. The
study will also investigate any possible side effects of the study drug ibrutinib.